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The first recipient of a cell transplant (blood transfusion) 
could have been Pope Innocent VIII in 1492, the donors being 
three youths. Donors and recipient died and no record of the 
procedure was left by the prescribing physician who disappeared 
under mysterious circumstances (1). 
Almost two centuries later the term "cell" was coined by 
Hooke (1) who described "little boxes or cells distinct from one 
another" in a piece of cork examined at the microscope. 
Pioneers in the early work on tissue culture and 
transplantation were Zahn (1878), Arnold (1887) (3), Williams 
(1893) (4), Born (1896), Harrison (1905) (3) and Carrel (1910) 
(5), but the real milestone in cell transplant history has been 
the introduction of protealitic enzymatic digestion to dissociate 
cells from tissue and organs. Rous and Jones first introduced 
trypsin to separate growing cells from tissue included in a 
plasma clot (6), but fear of damaging the cells by the enzymatic 
treatment (7) delayed the diffusion of the technique. The 
subsequent isolation of collagenase from Clostridium welchii in 
1946 (8) opened the way to the modern technology of cell 
separation and transplantation. 
Cellular transplant models share problems, advantages, and 
research targets. 
SEPARATION/PURIFICATION 
Retrieval of an adequate number of morphologically and 
functionally intact cells is the first requirement. Enzymatic 
digestion of tissues can potentially damage the cells during the 
separation procedure (7). Therefore, the progress in cell 
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separation technology has paralleled improvement in experimental 
and clinical transplantation results (9). 
REJECTION 
The major problem of cellular transplantation is the lack of 
effective procedures for early detection and treatment of 
rejection. The relatively small cell mass that is transplanted 
generally leads to difficulty in early diagnosis of rejection. 
In most of the cases it is too late to treat a rejection episode 
when it becomes manifest. The problem is even more dramatic when 
immature or fetal cells are transplanted because of the gap 
between the time of implantation and the beginning of functional 
activity of the graft that can be of months before any 
significant functional activity is detected. The absence of 
early graft function makes it even more difficult to detect and 
treat a rejection episode. 
Despite these problems, cellular transplantation offers 
unique advantages 
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In many cases a cell transplant is a simple injection or 
cell infusion that can be performed under local anesthesia. 
Percutaneous and laparoscopic approaches are also currently under 
evaluation. 
PRE-TRANSPLANT CELL TREATMENT 
The prospect to avoid continuous recipient immunosuppression 
by in-vitro treatment of the tissue before transplantation to 
decrease the immunogenicity of the graft is attractive (9-14). 
Several treatments have been proposed in the last 15 years, 
------------_ .. _. 
including low temperature, high oxygen, hyperthermic and 
hyperbaric cultures, monoclonal and policlonal antibody 
treatment, radiation, single cell dispersion and sorting and 
cryopreservation. 
IMMUNOISOLATION TECHNIQUES 
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The introduction of a physical barrier between the 
transplanted cells and the recipients immune system (15-17) is an 
attractive possibility and significant progress has been made 
towards the development of materials that do not stimulate 
fibroblastic response in the recipient. Clinical trials using 
immunoisolation devices are in progress and will provide critical 
information in the near future. 
CRYOPRESERVATION AND BANKING 
The possibility to cryopreserve cells (18-19) makes it 
possible to create banks of tissue for transplantation. This 
technology will allow to delay the time of transplantation, for 
example to provide sufficient time to induce donor specific 
unresponsiveness or tolerance. In addition, multiple donors 
could be used to increase the number of cells available to the 
recipient. Transplantation from multiple donors has been 
reported to result in graft acceptance in experimental models 
(20-21). Cryopreservation have been recently proposed also as a 
mean of immunoalteration of the tissue before transplantation. 
SITES OF IMPLANTATION 
Appropriate sites of implantation are required to ensure 
adequate vascular support for integration and reconstitution of 
the cellular graft. Transplantation in different sites can 
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result in different allograft and xenograft survival (22-26) 
CV 
introducing ~immunologically relevant variable. In addition, 
the microenvironment at the transplant site can affect 
engraftment of the transplanted cells. For example, the exposure 
to cytokines and the intrinsic ability of tissues to generate 
nitric oxide could lead to impaired engraftment/function of 
transplanted cells. 
The confirmation of the recent report of the formation of 
organoid neovascular structures after implantation of fibers 
coated with collagen and growth factors in the peritoneal cavity 
of rats (27) could lead to a variety of cellular transplant 
applications including implantation of autologous cells after 
restoration of a deficient function by gene transfer. In 
addition, the organoid neovascular structure makes it possible to 
confine a cellular implant in a well-defined, vascularized space 
which could be easily removed in case of adverse reaction. 
GENE THERAPY 
Viruses or other similar agents can be used as vehicles to 
introduce functional genes into human cells. Many cellular 
defects and genetic diseases could be treated by this approach 
(28-31). Approaches for gene therapy include gene replacement, 
gene correction, and gene augmentation. A mutant gene sequence 
can be replaced with a normal functional gene (gene replacement). 
More ideally, specific correction of a mutant gene sequence could 
be performed without any additional change in the target genome 
(gene correction). As an alternative, gene augmentation could be 
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used to modify the expression of the content of a mutant gene in 
defective cells. Several methods are available to deliver genes 
into mammalian cells (28) including: 1) co-precipitation with 
calcium phosphate; 2) use of polycations or lipids to complex 
with the DNA; 3) encapsidation of DNA into liposomes or 
erythrocyte ghosts; 4) exposure of the target cells to rapid 
pulses of high voltage current and 5) introduction of DNA into 
cells by direct microinjection. 
Retroviruses have been the most used viral vectors for their 
ability to infect a broad class of cell types. Nevertheless, 
they require cell replication and DNA synthesis, restricting 
their efficient use to cells that are able to replicate. Their 
characteristic of random integration in the cell genome 
introduces an additional negative factor: the risk of insertional 
mutagenesis. other vectors such as adeno-associated virus (AAV) 
and herpesviruses have been developed. In particular, AAV 
viruses are ubiquitous in humans and can be concentrated to very 
high titles. They are not pathogenic and require helper 
adenovirus or herpesvirus for replication. In addition, it is 
possible to achieve constant integration site decreasing the risk 
of mutagenesis that derives from random integration. 
Bone marrow has been one of the most attractive targets for 
gene therapy (30), the more studied models being the 
immunodeficiency diseases caused by defects of adenosine 
deaminase (ADA) and purine-nucleoside phosphorlyase, chronic 
granulomatous diseases and Gaucher's disease. Erythroid cell 
disorders of hemoglobin expression, including sickle cell anemia 
and the thalassemias are also theoretical targets for this 
approach. 
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Another target for gene therapy is the liver (33) and 
several genes have been expressed in primary hepatocyte cultures, 
including the disease-related genes for the human receptor for 
low-density liproteins, phenylalanine hydroxylase, and alphal-
antitrypsin. Research is now focusing on methods for the 
implantation of genetically modified hepatocytes and on the 
development of vectors that can be introduced directly into 
hepatocytes in-vivo. 
Models of gene therapy have been proposed for central 
nervous system diseases (28). Challenges in these applications 
include the fact that most target cells are postmitotic (neurons) 
and therefore refractory to infection with retroviral vectors. 
In addition, several disorders affecting the central nervous 
system are likely to be mUltigenic and multifactorial, the target 
cells being located in sites that are not easily accessible. 
Nevertheless, the potential role of gene therapy for the 
treatment of Alzheimer's disease and Parkinson's disease is 
currently the focus of intensive research. If gene transfer-
cellular transplant approaches are effective, it will be possible 
to treat genetic, developmental, degenerative, infectious, or 
traumatic central nervous system dysfunctions. 
Gene therapy applications have been proposed also for cancer 
treatment (28). In fact, deficiencies of cancer suppressor genes 
such as those apparently associated with retinoblastoma and 
Wilms' tumor could be treated by restoration of the expression of 
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the suppressor gene. Alternative approaches involve inactivation 
of dominantly acting oncogenes and antisense oligonucleotides to 
modulate the expression of oncogenes for the suppression of the 
cancer phenotype. The combination of gene transfer and cellular 
transplantation could become available to replace defective 
physiological products including hormones, serum proteins, and 
other metabolic products, in which transplantation of cells 
genetically modified could replace the compromised native 
sources. 
Many diseases have been proposed as theoretical target for 
gene therapy, including disorders of serum proteins such as 
(hemophilia), hormone deficiencies such (diabetes mellitus) (34), 
and other enzyme or gene product-deficiency diseases, such as 
alpha(l)-antitrypsin deficiency. 
BONE MARROW TRANSPLANTATION 
Disorders that can be treated by bone marrow transplantation 
include severe combined immunodeficiency states, leukemias, 
various inherited disorders, osteoporosis, and solid tumors. A 
recent review on the subject has been written by Hardy and 
Ikpeazu (35). The first reported marrow transfusion was in 1939 
to treat gold-induced aplasia (36). In 1957, Thomas reported the 
first series of human bone marrow recipients (37)-with transient 
positive results. Despite the advances in transplantation 
immunology and histocompatibility typing, the problems of 
rejection, graft-versus-host disease and infections still 
severely limit the success of this cellular transplant. 
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Development in molecular biology and genetic engineering may lead 
to new future applications. 
STEM CELL TRANSPLANTATION 
Hematopoietic progenitor cells, which are circulating in the 
blood can be isolated to replace marrow in certain circumstances 
in which a controindication for marrow harvest exists (38). 
Recently, human umbilical cord blood, that is usually discarded, 
have been used as a source of stern cells for clinical 
hematopoietic reconstitution (39), indicating that cord blood 
from a single individual could provide sufficient reconstituting 
cells for effective hematopoietic repopulation in an HLA-
compatible allogeneic recipient. 
NEURAL TRANSPLANTATION 
Neural Transplantation to the central nervous system is at 
an early stage of development. The work has evolved towards two 
main goals: 1. promote regeneration or recreate damaged central 
neural circuits. 2. replacement of a particular chemical that is 
lacking in the recipient as a result of a lesion or a genetic 
disorder. 
Neural transplantation has also attracted interest because 
of the reported prolonged survival of intracerebral grafts (23). 
Nevertheless, it became recently evident that even if cells can 
survive for prolonged periods after transplantation in this site, 
they survive in an immunologically unstable state and rejection 
can occur even after months of survival. 
Future applications of neural transplantation in man include 
Parkinson's disease, to replace the degenerated dopamine-
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containing input to the basal ganglia and Alzheimer's disease, in 
which the degeneration of the acethylcholine containing input to 
cerebral cortex and hippocampus could be corrected by 
implantation of fetal cholinergic brain cells into the cortex 
and/or hippocampus. 
Fetal hypothalamic cell grafts could be used to treat 
deficiencies of hypothalamic releasing factors (41) such as in 
the case of transplantation of hypothalamic cells to the third 
ventricle of mice with testicular or ovarian/uterine hypotrophy 
resulting from a deficiency in hypothalamic gonadotropin 
releasing hormone (GnRH). 
Finally, newborn rat retinal cells have been recently 
transplanted into an adult lesion site demonstrating integration 
and differentiation into the host retinal lesion site. 
EPIDERMAL CELL TRANSPLANTS 
Human epidermal cells from small skin biopsy samples have 
been recently used as a new source of autograft to treat patients 
with burns so extended that it is impossible to provide their 
complete coverage by skin grafts from the patient. In these 
cases epidermal cells can be cultured to produce epithelium 
sheets sufficient to cover the entire body surface (43-44). 
These cultured epithelial cells were initially used in the nude 
mouse model to demonstrate their ability to generate human 
epidermis after application to wounds (45). Their permanent 
epidermis was generated after transplantation on small burn 
wounds in adults and children (46-47). Successful treatment of 
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two children by cultured epithelial cells autografts to cover 
burns on more than 95% of their bodies was finally reported in 
1984 (48). The same technique for epidermal cell preparation has 
been recently adopted in experimental neonatal epidermal cell 
allotransplantation (49), in which indefinite survival of the 
epidermal cell allografts was obtained across minor and major 
histocompatibility barriers. 
MYOBLAST TRANSPLANTS 
The first attempts in human to correct Duchenne muscular 
dystrophy by muscle cell transplantation have been performed in 
the United states. In preliminary studies, muscle cells were 
injected in the muscle of the foot which controls the movement of 
a big toe of a 9 year boy affected by Duchenne muscular 
dystrophy. An increase of 20% in the muscle strength was 
announced. Several boys have been treated so far by muscle cell 
transplant using cyclosporine as immunosuppressive agent, and 
further studies are needed to determine the feasibility of this 
approach. 
HEPATOCYTE TRANSPLANTATION 
Experimental hepatocyte transplantation indicated that it is 
possible to retain hepatocellular functions after transplantation 
of isolated hepatocytes (50). The possibility to correct 
congenital enzyme deficiency diseases (51-53) in rodents and to 
improve the survival rate in acute hepatic failure models (54-56) 
by an hepatocellular transplants has also been observed. In 
1989, Moscioni et al. (57) showed that human liver cells attached 
to collagen coated microcarriers using a previous described 
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method (58-59), were able to function after transplantation into 
mutant rat recipients which were genetically deficient in either 
uridine diphosphoglucuronosyltransferase activity (Gunn rats) or 
albumin synthesis (Nagase analbuminemic rats). The animals were 
made genetically immunodeficient by interbreeding with athyrnic 
rats so that transplantation of human tissue was made possible 
without problems related to rejection. Interestingly the 
injected hepatocyte microcarriers have been found on the surface 
of the pancreas where newly formed blood vessels were present. 
This finding has raised again the issue of hepatotrophic factors 
and their role in the maintainence of hepatocytes transplanted in 
ectopic sites. In fact, initial reports of proliferation of 
hepatocytes transplanted into the spleen in the absence of direct 
perfusion by portal blood and in the presence of an intact host 
liver (50), were not confirmed in similar experimental conditions 
by Cuervas-Mons et ale (60) who reported no evidence of 
hepatocytes proliferation at any time after transplantation. In 
addition, it has been reported (61) that in the absence of a 
proliferative (70% of hepatectomy) in the recipient rats, it was 
not possible to detect the hepatocytes at either two or four days 
after intrasplenic transplantation. Cuervas-Mons et ale also 
reported that there was no evidence of hepatocytes seven days 
after allotransplantation in immunosuppressed rats (62). Cells 
without nuclei and multinucleated cells were detected at the 
transplant site, suggesting degeneration rather than rejection. 
It may be that in the model of Demetriou et ale (58-59) of 
collagen-coated microcarriers with attached hepatocytes the 
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microcarriers allow the survival of some of the hepatocytes. 
This may be due to a favorable effect of collagen matrix in the 
maintenance of hepatocyte in-vivo. The fact that hepatocytes-
microcarriers aggregates were found on the surface of the 
pancreas repropose the role of factors produced from the pancreas 
in the maintenance of normal hepatocyte. To address this 
problem, a series of recent experiments both using rodents 
(63,64) and human (65) hepatocytes clearly demonstrated the 
protective effect of islets co-transplanted with hepatocytes in 
the maintenance of the ectopic hepatocytes. These reports 
demonstrated that it is possible to maintain hepatocytes in an 
ectopic site with an intact host liver present by addition of 
pancreatic islets to the hepatocellular grafts, while in the 
absence of pancreatic islets, degeneration of the hepatocytes 
occurred. The addition of collagen microcarriers of the same 
type as previously described by (57-59), did not improve human 
hepatocyte survival leaving only a thin rim of epithelioid cells 
attached to the collagen microcarriers (65). This experimental 
model is an example of combined cellular transplants in which a 
cellular population allows or improves the engraftment of a 
second cellular type. These results confirmed the pioneer work 
of Starzl that clearly established the role of splanchnic-derived 
hepatotrophic factors in the maintenance of hepatocyte integrity 
(66-69) . 
PANCREATIC ISLET TRANSPLANTATION 
In 1893 Dr. Williams performed the first attempt of 
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pancreatic fragment graft in a fifteen year old diabetic child. 
The discovery of insulin 29 years later determined an enormous 
improvement in the care of diabetic patients, since it became 
possible to control hyperglycemia and ketoacidosis, that were the 
primary cause of death in these patients. Unfortunately, it 
became apparent that the secondary complications of diabetes 
which are now the primary cause of morbidity and mortality, have 
not been prevented by exogeneous insulin therapy. Islet 
transplantation has been proposed as an alternative treatment to 
replace the endocrine pancreatic function in a more physologic 
way. The procedures for isolation of the islet cells from the 
exocrine tissue have been pioneered by the work of Moskalewski 
(70) and Lacy (71). Lacy first introduced the concept of 
intraductal distention of the pancreas and collagenase digestion 
(71). A comprehensive review of the progress of experimental and 
clinical islet transplantation is now available (72). The most 
recent data of the islet transplant registry by Hering et al. 
show that before 1984 no islet transplant demonstrated 
significant islet function (C-peptide 1mg/ml) one month after 
transplantation. Between 1985 and 1989 a significant improvement 
in post-transplant islet function was observed. In fact, in over 
thirty percent of the cases, basal C-peptide production was 
observed in the first week post-transplant. But less than twenty 
percent had documented c-peptide production at one month. 
1990 was a critical year for islet transplantation because 
of the demonstration of the ability of allogenic purified human 
islets to achieve insulin independence after transplantation in 
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patients with pancreatectomy-induced type 1 diabetes. The first 
islet transplant of this series was performed in a fifteen year 
old girl who is still insulin independent 28 months following 
islet allotransplantation from a single donor (73). However, the 
preliminary trials of islet transplantation in Type 1 diabetic 
patients have been disappointing since only one patient is today 
still insulin free 2 years after allotransplantation of islets 
obtained from 5 donors. Several factors remain to be tested such 
as the adequacy of the implantation site, variables affecting 
islet engraftment, rejection, the diabetogenic effect of the 
immunosuppressive agents currently in use, and the role of the 
underlying autoimmune diseases. 
CELL TRANSPLANTATION TO INDUCE DONOR SPECIFIC TOLERANCE 
One of the most exciting developments in cell 
transplantation could be the possibility to use a cell transplant 
procedure to induce tolerance to cells, tissue and organs from 
syngeneic donors. Bone marrow transplantation has long been 
known to induce donor specific tolerance in recipient animals 
(74). Bone marrow is especially effective in its ability to 
confer tolerance to subsequent cellular, tissue or solid organ 
grafts from the same donor (75). Recently, we reported induction 
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of donor specific tolerance to pancreatic islets following bone 
marrow transplantation in fully xenogeneic rat to mouse chimeras 
(76). It is of interest that donor type bone marrow derived 
antigen presenting cells, including dendritic cells, repopulated 
the recipients ubiquitously (77). 
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The phenomenon of cell migration and repopulation after 
transplantation is not exclusive in bone marrow transplants. In 
fact, donor dendritic cell migration into recipients has been 
observed following solid organ transplants such as heart, liver 
and intestine (78). The presence of donor antigen presenting 
cells in the recipients of bone marrow or solid organ transplants 
appears to be proportional to the amount of lymphoid and 
dendritic cells in the donor tissue and these cells are thought 
to be related to the facilitation of graft acceptance. 
Studies are in progress to determine the relation between 
migration of donor antigen presenting cells, graft acceptance and 
the induction of donor specific tolerance. Co-transplantation of 
cells from bone marrow preparations may become in the future a 
requisite for tolerance induction to any allogeneic and 
xenogeneic transplant. 
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